The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling
Open accessAbstract
Poxviruses encode a large number of proteins that attenuate the inflammatory and immune responses to infection. In this report we demonstrate that a number of orthopoxviruses express a type I interferon (IFN)-binding protein, which is encoded by the B18R open reading frame in the WR strain of vaccinia virus. The B18R protein has significant regions of homology with the alpha subunits of the mouse, human, and bovine type I IFN receptors, bound human IFN alpha 2 with high affinity, and inhibited transmembrane signaling as demonstrated by inhibition of Fc receptor factor gamma 1/gamma 2 and interferon-stimulated gene factor-3 formation as well as inhibition of the IFN alpha antiviral response. Among viral host response modifiers, the B18R protein is unique inasmuch as it exists as a soluble extracellular as well as a cell surface protein and thus should effectively block both autocrine and paracrine functions of IFN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Structural design and molecular evolution of a cytokine receptor superfamily.
Bazan, J. F. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.6934 · Cited by 2,069
Pestka, S., Langer, J. A., Zoon, K. C., & Samuel, C. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003455 · Cited by 1,825
A workbench for multiple alignment construction and analysis
Schuler, G. D., Altschul, S. F., & Lipman, D. J. (1991) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340090304 · Cited by 985
A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins
Smith, C. A., Davis, T., Anderson, D., Solam, L., Beckmann, M. P., Jerzy, R., Dower, S. K., Cosman, D., & Goodwin, R. G. (1990) · Science · doi:10.1126/science.2160731 · Cited by 959
Inhibition of Viral Replication by Interferon-γ-Induced Nitric Oxide Synthase
Karupiah, G., Xie, Q.-W., Buller, R. M. L., Nathan, C., Duarte, C., & MacMicking, J. D. (1993) · Science · doi:10.1126/science.7690156 · Cited by 816
Self-citationThe protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction
Müller, M., Briscoe, J., Laxton, C., Guschin, D., Ziemiecki, A., Silvennoinen, O., Harpur, A. G., Barbieri, G., Witthuhn, B. A., Schindler, C., et al. (1993) · Nature · doi:10.1038/366129a0 · Cited by 760
Uzé, G., Lutfalla, G., & Gresser, I. (1990) · Cell · doi:10.1016/0092-8674(90)90738-z · Cited by 574
Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins
Shuai, K., Ziemiecki, A., Wilks, A. F., Harpur, A. G., Sadowski, H. B., Gilman, M. Z., & Darnell, J. E. (1993) · Nature · doi:10.1038/366580a0 · Cited by 509
Chang, H. W., Watson, J. C., & Jacobs, B. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4825 · Cited by 483
Cited by
Antiviral Actions of Interferons
Samuel, C. E. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.778-809.2001 · Cited by 2,743
Interferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,766
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Randall, R. E., & Goodbourn, S. (2008) · Journal of General Virology · doi:10.1099/vir.0.83391-0 · Cited by 1,571
Viruses and interferon: a fight for supremacy
Katze, M. G., He, Y., & Gale, M. (2002) · Nature Reviews Immunology · doi:10.1038/nri888 · Cited by 1,419
“The vaccinia-virus B18R open reading frame also encodes a soluble IFN-α/β receptor that blocks the binding of IFN-α/β to cell-surface receptor”
BackgroundI nterleukin -10 and R elated C ytokines and R eceptors
Pestka, S., Krause, C. D., Sarkar, D., Walter, M. R., Shi, Y., & Fisher, P. B. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104622 · Cited by 1,094
Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor
Yao, Z., Fanslow, W. C., Seldin, M. F., Rousseau, A.-M., Painter, S. L., Comeau, M. R., Cohen, J. I., & Spriggs, M. K. (1995) · Immunity · doi:10.1016/1074-7613(95)90070-5 · Cited by 994
Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures
Goodbourn, S., Didcock, L., & Randall, R. E. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-10-2341 · Cited by 977
Seet, B. T., Johnston, J. B., Brunetti, C. R., Barrett, J. W., Everett, H., Cameron, C., Sypula, J., Nazarian, S. H., Lucas, A., & McFadden, G. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141049 · Cited by 666
Interferon signalling network in innate defence
Takaoka, A., & Yanai, H. (2006) · Cellular Microbiology · doi:10.1111/j.1462-5822.2006.00716.x · Cited by 581
Viral mimicry of cytokines, chemokines and their receptors
Alcami, A. (2003) · Nature Reviews Immunology · doi:10.1038/nri980 · Cited by 558
Monkeypox: disease epidemiology, host immunity and clinical interventions
Lum, F.-M., Torres-Ruesta, A., Tay, M. Z., Lin, R. T. P., Lye, D. C., Rénia, L., & Ng, L. F. P. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00775-4 · Cited by 541
Antoine, G., Scheiflinger, F., Dorner, F., & Falkner, F. G. (1998) · Virology · doi:10.1006/viro.1998.9123 · Cited by 507
The interferons and their receptors—distribution and regulation
de Weerd, N. A., & Nguyen, T. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2012.9 · Cited by 480
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459
The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion
Levy, D. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00027-7 · Cited by 428
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity
Smith, G. L., Benfield, C. T. O., Maluquer de Motes, C., Mazzon, M., Ember, S. W. J., Ferguson, B. J., & Sumner, R. P. (2013) · Journal of General Virology · doi:10.1099/vir.0.055921-0 · Cited by 364
Blanchard, T. J., Andrea, P., Alcami, A., & Smith, G. L. (1998) · Journal of General Virology · doi:10.1099/0022-1317-79-5-1159 · Cited by 336
York, M. R., Nagai, T., Mangini, A. J., Lemaire, R., van Seventer, J. M., & Lafyatis, R. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22382 · Cited by 327
Monkeypox virus and insights into its immunomodulatory proteins
Weaver, J. R., & Isaacs, S. N. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00691.x · Cited by 295
Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing
Wilbie, D., Walther, J., & Mastrobattista, E. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00106 · Cited by 294
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Guo, Z. S., Lu, B., Guo, Z., Giehl, E., Feist, M., Dai, E., Liu, W., Storkus, W. J., He, Y., Liu, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0495-7 · Cited by 292
Alcamı́, A., Symons, J. A., & Smith, G. L. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.11230-11239.2000 · Cited by 273
Class II cytokine receptors and their ligands: Key antiviral and inflammatory modulators
Renauld, J.-C. (2003) · Nature Reviews Immunology · doi:10.1038/nri1153 · Cited by 265
Blockade of Chemokine Activity by a Soluble Chemokine Binding Protein from Vaccinia Virus
Alcamí, A., Symons, J. A., Collins, P. D., Williams, T. J., & Smith, G. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.2.624 · Cited by 252
The Type I Interferon Receptor: Structure, Function, and Evolution of a Family Business
Mogensen, K. E., Lewerenz, M., Reboul, J., Lutfalla, G., & Uzé, G. (1999) · Journal of Interferon & Cytokine Research · doi:10.1089/107999099313019 · Cited by 252
Oncolytic virus-derived type I interferon restricts CAR T cell therapy
Evgin, L., Huff, A. L., Wongthida, P., Thompson, J., Kottke, T., Tonne, J., Schuelke, M., Ayasoufi, K., Driscoll, C. B., Shim, K. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17011-z · Cited by 128
Matsa, E., Ahrens, J. H., & Wu, J. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00036.2015 · Cited by 105
“Initial reprogramming experiments using mRNA transfection required a laborious series of consecutive mRNA transfections for 14 days, as well as pretreatment of target cells with the expensive interferon- antagonist B18R (177) to prevent cell death from repeated mRNA transfections (44).”
BackgroundRate, A., Upham, J. W., Bosco, A., McKenna, K. L., & Holt, P. G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.72 · Cited by 88
Metadata
- Authors
- Colamonici, O. R., Domanski, P., Sweitzer, S. M., Larner, A., & Buller, R. M. L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1995-07
- Volume
- 270
- Issue
- 27
- Pages
- 15974-15978
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2027434594
- Cited by
- 386
- References
- 34
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.